Key takeaways
- • Trial: SUSTAIN-1 (NCT02054897) — Phase 3a, 388 participants over 30 weeks.
- • Drug studied: Ozempic (Semaglutide) — FDA-approved branded product.
- • Primary endpoint: Change in HbA1c from baseline to week 30 in drug-naive adults with type 2 diabetes
- • Key result: HbA1c reduction 1.45% (semaglutide 0.5mg) and 1.55% (semaglutide 1.0mg) vs 0.02% on placebo
- • Published: The Lancet Diabetes & Endocrinology, 2017.
Study design
SUSTAIN-1 was a phase 3a randomized controlled trial enrolling 388 participants over 30 weeks. The trial studied Ozempic (Semaglutide) for type 2 diabetes and was published in The Lancet Diabetes & Endocrinology in 2017.
Primary endpoint
Change in HbA1c from baseline to week 30 in drug-naive adults with type 2 diabetes
Key results
| Measure | Value |
|---|---|
| Headline result | HbA1c reduction 1.45% (semaglutide 0.5mg) and 1.55% (semaglutide 1.0mg) vs 0.02% on placebo |
| HbA1c reduction (highest dose arm) | -1.55 percentage points |
| Participants | 388 |
| Duration | 30 weeks |
| Phase | Phase 3a |
Citation
SUSTAIN-1. Published in The Lancet Diabetes & Endocrinology, 2017.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Ozempic drug page — pricing, FDA status, side effects, alternatives
- All semaglutide trials
- GLP-1 clinical trials database
Other Ozempic trials
- SUSTAIN-6 — 26% relative risk reduction in MACE on semaglutide vs placebo (HR 0
Other Semaglutide trials
- STEP-1 (Wegovy) — Mean weight loss 14
- STEP-2 (Wegovy) — Mean weight loss 9
- STEP-3 (Wegovy) — Mean weight loss 16
- STEP-4 (Wegovy) — Participants continuing semaglutide lost an additional 7
- STEP-5 (Wegovy) — Mean weight loss 15
Important: This trial was conducted on the FDA-approved branded product Ozempic. Compounded versions of Semaglutide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.